Stocks
Cassava Sciences, Inc.SAVA
NASDAQHealthcareBiotechnology$2.09-12.18%
Price as of · delayed, not real-time
Focused on developing treatments for Alzheimer's disease, this biopharmaceutical company has garnered investor attention for its experimental drug candidate, simufilam, which targets neurodegeneration. Its stock is closely monitored due to the high-stakes nature of Alzheimer's research and its potential market impact.
Market Cap: $101.0M52W Range: $1.15-$4.98
Congressional Interest in Cassava Sciences, Inc. (SAVA)
1 member of Congress has disclosed 5 trades in Cassava Sciences, Inc. (SAVA), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 2 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
5
Unique Politicians
1
Buys
3
Sells
2
Who in Congress Is Trading SAVA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Christopher L. Jacobs | buy | $1K-$15K |
| 2022-11-08 | Christopher L. Jacobs | sell | $1K-$15K |
| 2022-10-12 | Christopher L. Jacobs | buy | $1K-$15K |
| 2022-07-18 | Christopher L. Jacobs | sell | $1K-$15K |
| 2022-06-21 | Christopher L. Jacobs | buy | $15K-$50K |